Soligenix rallies after Chief Scientific Officer authors paper in ScienceDirect

Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection, ScienceDirect claims in a post dated December 28. The vaccine candidates provided 100% protection against severe and lethal filovirus disease after either Filoviridae, Sudan ebolavirus or Marburg marburgvirus infection, according the scientific journal. Although mild, subclinical infection was observed in a few macaques, all vaccinated animals remained healthy and survived the filovirus challenge. “These results demonstrate the value that thermostabilized protein vaccines could provide for addressing an important gap in preparedness for future filovirus outbreaks,” ScienceDirect added. Oreola Donini, the Chief Scientific Officer of Soligenix (SNGX), is one of the authors of the paper and a named inventor on a patent covering multivalent filovirus subunit vaccines. Shares of Soligenix are up 19% to 80c following dissemination of the journal article.